News › Industry News, News

Allergan is buying CoolSculpting provider Zeltiq for $2.48 billion

February 14, 2017

Botox maker Allergan is spending about $2.48 billion to buy Zeltiq Aesthetics Inc. and its CoolSculpting system for reducing fat.
Allergan said it will pay $56.50 for each share of Zeltiq in a deal it expects to close in the second half of this year. That represents a 14% premium to Zeltiq’s Friday closing price of $49.40. The Pleasanton, Calif., company’s shares jumped 13.2% on Monday to $55.93. 
Allergan, based in Dublin, Ireland, said the deal will strengthen an aesthetics business that already includes plastic surgery and regenerative treatments.
Zeltiq’s nonsurgical system cools fat cells to trigger their controlled elimination without affecting the surrounding tissue, according to Allergan. 
Read more at Los Angeles Times >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Compounded Tirzepatide, NAD+ Injections Recalled Nationwide Over Sterility Concerns
    • Meliora Consulting Becomes Silver Vendor Affiliate with the American Med Spa Association
    • FDA Sends Peptide ‘Interim Access Policy’ to White House for Review
    • New ACOG Menopause Guidelines Expand Hormone Therapy and Symptom Treatment Recommendations
    • Galderma to Acquire ZO Skin Health for $1.5 Billion
Advertisement